Allergic Rhinitis
Conditions
Interventions
Experimental Group:Qifeng Shengshi Formula
Sponsors
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age 18–65 years; either sex. 2.History of perennial allergic rhinitis (PAR) for =2 years. 3.Serum specific IgE =0.7 kUA/L to at least one perennial allergen (e.g., dust mites, mold, animal dander); if animal dander, history of animal exposure is required. 4.Meeting the TCM syndrome differentiation criteria for Wind invading the nose with Dampness stagnation and Blood stasis pattern. 5.Voluntary participation with signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with allergic rhinitis during the pollen season. 2. Those who have undergone any nasal or sinus surgery, allergen-specific immunotherapy, biologics, or systemic hormonal therapy within the past year. 3. Other allergic diseases in the acute phase, such as allergic asthma or atopic dermatitis, and other acute or chronic severe diseases deemed by the investigator. 4. Individuals allergic to any components of the investigational drug (Qifeng Shengshi Formula or loratadine). 5. Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Nasal Symptom Score (TNSS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Rescue Medication Score (RMS);Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ);TCM Syndrome Score;AR Symptom Recurrence Time; | — |
Countries
China
Contacts
Public ContactSun Qing
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Outcome results
None listed